Sevelamer
- Generic Name
- Sevelamer
- Brand Names
- Renagel, Renvela, Sevelamer carbonate Winthrop (previously Sevelamer carbonate Zentiva)
- Drug Type
- Small Molecule
- Chemical Formula
- C6H12ClNO
- CAS Number
- 52757-95-6
- Unique Ingredient Identifier
- 941N5DUU5C
Overview
Sevelamer is a phosphate binding drug used to prevent hyperphosphataemia in patients with chronic renal failure. It is marketed by Genzyme under the trade name Renagel.
Background
Sevelamer is a phosphate binding drug used to prevent hyperphosphataemia in patients with chronic renal failure. It is marketed by Genzyme under the trade name Renagel.
Indication
For the control of serum phosphorus in patients with Chronic Kidney Disease (CKD) on hemodialysis.
Associated Conditions
- Hyperphosphataemia
Clinical Trials
FDA Approved Products
Sevelamer Carbonate
Manufacturer:NCS HealthCare of KY, Inc dba Vangard Labs
Route:ORAL
Strength:800 mg in 1 1
Approved: 2018/12/05
NDC:0615-8239
Sevelamer Carbonate For Oral Suspension
Manufacturer:Hangzhou Anprime Biopharm Co., Ltd.
Route:ORAL
Strength:800 mg in 1 1
Approved: 2023/03/24
NDC:72823-301
SEVELAMER CARBONATE
Manufacturer:Aurobindo Pharma Limited
Route:ORAL
Strength:2400 mg in 1 1
Approved: 2023/12/08
NDC:65862-931
Sevelamer carbonate
Manufacturer:Cipla USA Inc.
Route:ORAL
Strength:800 mg in 1 1
Approved: 2023/01/18
NDC:69097-967
Sevelamer Carbonate
Manufacturer:Major Pharmaceuticals
Route:ORAL
Strength:800 mg in 1 1
Approved: 2019/12/10
NDC:0904-6707
Singapore Approved Products
No Singapore products found for this drug
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.
© Copyright 2025. All Rights Reserved by MedPath